8-K: Cullinan Therapeutics Reports Q2 Loss, Advances Pipeline

Cullinan Therapeutics announced its second quarter 2025 financial results, reporting an increased net loss while highlighting significant progress across its immunology and oncology clinical programs and strategic board appointments.

Summary

• Cullinan Therapeutics reported a net loss of $70.1 million for the second quarter of 2025, compared to $42.0 million for the same period in 2024.
• Research and development expenses increased to $61.0 million in Q2 2025 from $36.3 million in Q2 2024.
• Cash, cash equivalents, shortand long-term investments, and interest receivable stood at $510.9 million as of June 30, 2025, with a projected cash runway into 2028.
• The CLN-978 program is actively enrolling patients across Phase 1 studies for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjogren's disease.
• Cullinan in-licensed velinotamig, a BCMA-directed bispecific T cell engager, from Genrix Bio for an upfront fee of $20 million, with potential milestones up to $692 million.
• Results from the pivotal Phase 2b REZILIENT1 study of zipalertinib were shared at ASCO 2025 and published in the Journal of Clinical Oncology.
• Taiho, Cullinan's partner, plans to submit a New Drug Application (NDA) for zipalertinib in relapsed EGFR ex20ins NSCLC by the end of 2025, pending FDA discussions.
• Enrollment continues for CLN-049 in Phase 1 studies for relapsed/refractory AML/MDS, with clinical data expected in Q4 2025.
• Mittie Doyle, M.D., and Andrew Allen, M.D., Ph.D., were appointed to the Board of Directors, effective August 7, 2025, following the resignations of Anne-Marie Martin, Ph.D., and David Ryan, M.D.

Sentiment

Score: 6

Explanation: While the company reported an increased net loss and higher R&D expenses, which are negative financially, these are expected for a clinical-stage biotech. The significant progress across multiple clinical programs, including a planned NDA submission, strategic in-licensing, and strong cash runway into 2028, indicate positive operational momentum and a solid foundation for future value creation.

Positives

• Cash, cash equivalents, investments, and interest receivable of $510.9 million as of June 30, 2025, provides a projected cash runway into 2028.
• CLN-978 program is actively enrolling across three Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjogren's disease, with initial safety data for SLE expected in Q4 2025.
• Successful in-licensing of velinotamig (BCMAxCD3 bispecific T cell engager) from Genrix Bio, expanding the immunology portfolio and leadership in T cell engagers for autoimmune diseases.
• Positive results from the pivotal Phase 2b REZILIENT1 study of zipalertinib were shared at ASCO 2025 and published in a peer-reviewed journal.
• Taiho plans to submit an NDA for zipalertinib in relapsed EGFR ex20ins NSCLC by the end of 2025, indicating significant regulatory progress.
• Appointment of two highly experienced directors, Mittie Doyle, M.D., and Andrew Allen, M.D., Ph.D., with deep expertise in immunology and oncology clinical development, strengthens the Board.

Negatives

• Net loss attributable to Cullinan increased significantly to $70.1 million for Q2 2025, compared to $42.0 million for Q2 2024.
• Research and development expenses increased to $61.0 million for Q2 2025, up from $36.3 million for the same period in 2024, indicating higher operational burn.
• Cash, cash equivalents, investments, and interest receivable decreased from $606.9 million at December 31, 2024, to $510.9 million at June 30, 2025.

Risks

• Uncertainty regarding the timing and results of regulatory submissions for product candidates.
• Risk that INDs, NDAs, or other global regulatory submissions may not be cleared on expected timelines, or at all.
• The success of clinical trials and preclinical studies is not guaranteed.
• Risks related to the company's ability to protect and maintain its intellectual property position.
• Risks associated with manufacturing, supply, and distribution of product candidates.
• Risk that any product candidates, including co-developed ones, will not be successfully developed and commercialized.
• The results of preclinical studies or clinical studies may not be predictive of future results in connection with future studies.
• Potential impact of changes in global economic conditions, including uncertainties related to international trade policies, tariffs, and supply chain dynamics, on business and operations.
• The success of any collaboration, partnership, or license agreements is not assured.

Future Outlook

Cullinan Therapeutics anticipates sharing initial safety and B cell depletion data for CLN-978 in SLE in Q4 2025, and initial data for CLN-978 in RA in H1 2026. Taiho plans to submit an NDA for zipalertinib in relapsed EGFR ex20ins NSCLC by the end of 2025, pending FDA discussions, and expects to complete enrollment of the frontline REZILIENT3 study in H1 2026. Clinical data for CLN-049 in relapsed/refractory AML and MDS is expected in Q4 2025. The company projects its current cash resources to provide runway into 2028.

Management Comments

• "I am proud of the team’s strong execution throughout the first half of the year as we continue to advance the CLN-978 program across three active studies in SLE, RA, and Sjogren’s disease."
• "With the addition of velinotamig, we further solidified our leadership position in the development of T cell engagers for autoimmune diseases. With these two programs, our portfolio covers the entire breadth of the B cell compartment."
• "Recent data presented at the European Alliance of Associations for Rheumatology (EULAR) meeting reinforced the potential of T cell engagers as disease-modifying therapies across a wide spectrum of autoimmune diseases."
• "We also continue making important progress across our oncology portfolio, recently sharing results from the pivotal Phase 2b portion of the REZILIENT1 study of zipalertinib at the 2025 ASCO Annual Meeting, and we look forward to sharing multiple new data sets at upcoming medical conferences."
• "Pending discussions with the U.S. FDA, our partner Taiho plans to submit an NDA in relapsed EGFR ex20ins NSCLC later this year and expects to complete enrollment of the frontline study REZILIENT3 in the first half of 2026."
• "We also plan to share clinical data for CLN-049, our FLT3xCD3 bispecific T cell engager, in patients with relapsed/refractory AML and MDS later this year."
• "With $510.9 million in cash and investments and runway into 2028, we have the resources to generate multiple value-driving catalysts near term and beyond across both our immunology and oncology programs."
• "I am pleased to welcome Drs. Mittie Doyle and Andrew Allen to our Board of Directors. They are proven leaders with deep strategic and development expertise in immunology and oncology, respectively, and I believe their contributions will be invaluable as we continue to advance our programs."
• "I would also like to thank Drs. Anne-Marie Martin and David Ryan for their contributions to our progress and success over the last several years."

Industry Context

Cullinan Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on targeted therapies for autoimmune diseases and cancer. The in-licensing of velinotamig and the advancement of T cell engagers align with a broader industry trend towards precision medicine and immunotherapies for both oncology and autoimmune conditions. The progress of zipalertinib in EGFR ex20ins NSCLC addresses a specific unmet need in lung cancer, a field with significant ongoing research and development. The company's strategy of building a diversified portfolio across modalities and therapeutic areas is common among biotech firms seeking to mitigate risk and maximize potential returns.

Comparison to Industry Standards

• The increase in R&D expenses and net loss is typical for a clinical-stage biopharmaceutical company actively advancing multiple programs, reflecting significant investment in drug development.
• The cash runway into 2028 is a strong financial position for a biotech of this stage, providing ample time to reach key clinical milestones without immediate capital raise pressure, which compares favorably to many smaller biotechs with shorter runways.
• The in-licensing deal for velinotamig, with its upfront payment and substantial milestone potential, is consistent with industry practices for acquiring promising early-stage assets, similar to deals seen with companies like Genmab or Seagen (prior to acquisition) in the bispecific antibody space.
• The planned NDA submission for zipalertinib by Taiho positions the program for potential market entry, a critical milestone that few clinical-stage assets achieve, comparable to the regulatory progress of other targeted therapies in NSCLC such as those developed by AstraZeneca (Tagrisso) or Takeda (Exkivity) for specific EGFR mutations.
• The appointment of seasoned industry veterans like Dr. Doyle (ex-Avalo, Aro, CSL Behring, Shire, Flexion, DICE Therapeutics board) and Dr. Allen (co-founder Gritstone bio, Clovis Oncology, Pharmion, board member Adaptimmune, Sierra Oncology, Epizyme) to the board is a common strategy for biotech companies to enhance governance and strategic oversight, leveraging their extensive experience in clinical development and corporate leadership.

Management Changes

Corporate Governance

Related Party Transactions

• No arrangements or understandings between Dr. Doyle and any other person pursuant to which she was appointed as a director.
• Dr. Doyle was not involved in any transactions with the Company exceeding $120,000 since the beginning of the Company’s last fiscal year, and there are no such currently proposed transactions.
• No arrangements or understandings between Dr. Allen and any other person pursuant to which he was appointed as a director.
• Dr. Allen was not involved in any transactions with the Company exceeding $120,000 since the beginning of the Company’s last fiscal year, and there are no such currently proposed transactions.

Stakeholder Impact

• **Shareholders**: Increased net loss and R&D expenses indicate higher burn rate, but a strong cash runway into 2028 provides financial stability. Pipeline advancements and planned NDA submission offer potential for future value creation and catalysts. Board appointments bring enhanced expertise.
• **Employees**: Continued investment in R&D and pipeline expansion suggests stable to growing employment opportunities within the company's development teams.
• **Customers (Future Patients)**: Progress in multiple clinical programs, particularly the planned NDA submission for zipalertinib and advancements in autoimmune disease therapies, indicates potential for new treatment options in areas of high unmet medical need.
• **Suppliers/Partners**: The in-licensing deal with Genrix Bio and ongoing collaboration with Taiho Oncology demonstrate active engagement with external partners, potentially leading to further business opportunities for suppliers and collaborators.
• **Creditors**: The substantial cash position and projected runway into 2028 suggest a strong liquidity profile, reducing immediate concerns for creditors.

Next Steps

• Share initial safety and B cell depletion data from Part A of the CLN-978 Phase 1 study in SLE in Q4 2025.
• Share initial data from the CLN-978 Phase 1 study in rheumatoid arthritis during the first half of 2026.
• Genrix Bio to initiate a Phase 1 study of velinotamig in patients with autoimmune diseases in China by the end of 2025.
• Taiho to share updated efficacy and safety data for zipalertinib in patients previously treated with amivantamab at the IASLC 2025 WCLC.
• Taiho to submit an NDA for zipalertinib in relapsed EGFR ex20ins NSCLC by the end of 2025, pending discussions with the U.S. FDA.
• Taiho to complete enrollment of the pivotal REZILIENT3 study in 1L EGFR ex20ins NSCLC in the first half of 2026.
• Taiho to share initial data from the REZILIENT2 cohort exploring zipalertinib in patients with uncommon EGFR mutations at the IASLC 2025 WCLC.
• Taiho to share initial data from the REZILIENT2 cohort exploring zipalertinib in patients with active brain metastases at the ESMO Congress 2025.
• Share clinical data for CLN-049 in patients with relapsed/refractory AML and MDS in Q4 2025.

Key Dates

Recommendation

While Cullinan Therapeutics reported an increased net loss and higher R&D expenses, which are typical for a clinical-stage biotech, the company maintains a robust cash position with a runway into 2028. The significant progress across multiple clinical programs, including a planned NDA submission for zipalertinib and advancements in its immunology pipeline, provides strong future catalysts. The strategic board appointments further strengthen the company's leadership. The stock is a 'hold' as investors should monitor the upcoming data readouts and the NDA submission for zipalertinib, which are critical for de-risking the pipeline and demonstrating commercial potential, balancing the current burn rate with future growth prospects.

Keywords

Biopharmaceutical, Oncology, Immunology, Clinical Trials, Drug Development, T Cell Engagers, EGFR ex20ins NSCLC, Autoimmune Diseases, AML, MDS, SEC Filing, Financial Results